Table 2. Baseline characteristics by AKI acquisition.
| Variable | AKI acquisition | p-value | |
|---|---|---|---|
| CA-AKI (N = 202) | HA-AKI (N = 135) | ||
| Age [years], mean (SD) | 58.1 (15.7) | 58.4 (15.4) | 0.74 |
| Male [N (%)] | 132 (65.3) | 95 (70.3) | 0.33 |
| Body Mass Index [kg/m2], mean (SD) | 27.7 (7.6) | 27.5 (4.5) | 0.23 |
| Comorbidities [N (%)] | |||
| Diabetes | 106 (52.4) | 52 (38.5) | 0.01* |
| Hypertension | 118 (58.4) | 53 (39.2) | <0.001* |
| CKD | 61 (30.1) | 20 (14.8) | 0.001* |
| Stroke | 13 (6.4) | 9 (6.6) | 0.64 |
| COPD | 12 (5.9) | 2 (1.4) | 0.04* |
| Admission biochemical data, mean (SD) | |||
| Serum Ferritin [ng/m] | 1325 (1259) | 1725 (4424) | 0.47 |
| Serum Leukocytes [109/L] | 4.0 (6.3) | 5.0 (5.5) | 0.09 |
| Serum Lymphocytes [μL] | 1032 (2139) | 1044 (1122) | 0.04* |
| Serum Hemoglobin [g/dL] | 12.8 (2.9) | 13.8 (1.8) | 0.003* |
| Serum Platelets [109/L] | 231 (101) | 255 (328) | 0.70 |
| Serum Sodium [mEq/L] | 135 (6.6) | 136.3 (5.3) | 0.46 |
| Serum Potassium [mEq/L] | 4.6 (1.0) | 4.1 (0.6) | <0.001* |
| Arterial pH | 7.37 (0.1) | 7.41 (0.1) | 0.07 |
| Serum bicarbonate [mEq/L] | 19.9 (4.5) | 21.9 (4.5) | 0.01* |
| Serum Creatinine [mg/dL] | 3.8 (5.9) | 1.3 (1.7) | <0.001* |
| COVID severity [N (%)] | 0.43 | ||
| Mild | 88 (43.5) | 53 (39.2) | |
| Severe | 114 (56.5) | 82 (60.8) | |
| AKI | |||
| KDIGO-1 | 64 (31.6) | 41 (30.3) | 0.87 |
| KDIGO-2 | 49 (24.2) | 33 (24.4) | 0.88 |
| KDIGO-3 | 89 (44.1) | 61 (45.1) | 0.76 |
| KRT | 60 (29.7) | 27 (20.0) | 0.04* |
| Need in mechanical lung ventilation [N (%)] | 80 (39.6) | 66 (48.8) | 0.09 |
| Length of stay, days, mean (SD) | 11.0 (7.4) | 12.0 (7.4) | 0.20 |
| Disposition [N (%)] | 0.06 | ||
| Discharged | 109 (53.9) | 59 (43.7) | |
| Expired | 93 (46.1) | 76 (56.3) | |
AKI, acute kidney injury; CA-AKI, community-acquired AKI; HA-AKI, hospital-acquired AKI; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; KRT, kidney replacement therapy.